CareDx says Keith Kennedy to take on CFO duties Feb. 26

CareDx says Keith Kennedy to take on CFO duties Feb. 26

CareDx Announces Transition of CFO Responsibilities to COO Keith Kennedy Effective February 26
February 24, 2026

CareDx, Inc. (Nasdaq: CDNA), a precision medicine company specializing in transplant patient care, announced that Keith Kennedy, its Chief Operating Officer (COO), will assume the role of Chief Financial Officer (CFO) effective February 26, 2026. Nathan Smith, the current CFO, disclosed his decision to step down during the company's quarterly earnings call.

Kennedy, who has served as COO since September 2024, brings over two decades of executive experience in healthcare, finance, and operations. Prior roles include CFO at PharmaLogic Holdings Corp (April 2022–September 2024) and leadership positions at Veracyte, MCG Capital Corporation, and GE Capital. A Chartered Financial Analyst and Certified Public Accountant, Kennedy holds an MBA from the College of William & Mary and a B.S. in Accounting from Indiana University according to company announcements.

The transition follows CareDx's strategic focus on expanding its genomic testing and digital health solutions for transplant patients. The company's integrated offerings include non-invasive molecular diagnostics for heart, kidney, and lung transplants, as well as laboratory and patient support services.

CareDx emphasized that Kennedy's dual role as COO and interim CFO aligns with its operational efficiency goals. The appointment reflects confidence in his ability to manage financial strategy while maintaining operational oversight. No immediate successor for Smith has been named, and the transition is not anticipated to disrupt ongoing financial reporting or corporate operations.

As with all forward-looking statements, risks and uncertainties may affect CareDx's future performance, including those outlined in its SEC filings, such as the Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

This article is based on publicly available information from CareDx's press releases and investor disclosures.